Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 9Uterine Cervical Dysplasia 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Bevacizumab 27Leucovorin 23Fluorouracil 22Oxaliplatin 17Irinotecan 15Cetuximab 14pembrolizumab 11IFL protocol 11Panitumumab 10Folfox protocol 10Capecitabine 10Gemcitabine 7adagrasib 5Cisplatin 5Carboplatin 5Ramucirumab 4Colonoscopy 4veliparib 3spartalizumab 3selpercatinib 3regorafenib 3labetuzumab 3durvalumab 3conatumumab 3cemiplimab 3Pemetrexed 3Paclitaxel 3HMPL-013 3Drug Therapy 35,11-methenyltetrahydrohomofolate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colonic Neoplasms × 5-aminolevulinic acid hexyl ester × Clear all
NCT01344902 2013-10-23

An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon

Photocure

Phase 1/2 Terminated
13 enrolled
Gastrointestinal

Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡